Skip to main content
Log in

The effects of a somatostatin analogue on the metabolism of an infant with Beckwith-Wiedemann syndrome and hyperinsulinaemic hypoglycaemia

  • Endocrinology
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Hypoglycaemia is a frequent finding during the neonatal period and may be due to insulin overproduction. Patients with Beckwith-Wiedemann syndrome have reduced numbers of somatostatin-producing cells and decreased extractable somatostatin. In this study the effect of long-acting somatostatin (SMS 201–995) on the glucose and insulin levels in an infant with Beckwith-Wiedemann syndrome and hyperinsulinaemic non-ketotic hypoglycaemia is described. SMS 201–995 lowered basal insulin levels while maintaining normal glucose and insulin homeostasis. During fasting however, both glucose levels declined rapidly whereas insulin levels did not. The absence of both ketosis and elevated levels of free fatty acids and lactate during hypoglycaemia, as observed in our patient, are important diagnostic clues since the insulin levels themselves may sometimes be only slightly elevated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

SMS 201–995:

long-acting somatostatin

References

  1. Aynsley-Green A (1981) Nesidioblastosis of the pancreas. In: Randle PJ, Steiner DF, Whelan WJ (eds) Carbohydrate metabolism and its disorders. Academic Press, London, pp 181–204

    Google Scholar 

  2. Aynsley-Green A (1989) In: Brook CGD (ed) Clinical paediatic endocrinology, 2nd ed 1, Blackwell Scientific Publications, Oxford, pp 627–628

    Google Scholar 

  3. Bauer W, Brimer V, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Aynsley-Green 31:1133–1141

    Google Scholar 

  4. Beckwith JB (1969) Birth defects. Original Article Series 1969, Vol V, 2:188

    Google Scholar 

  5. Besser GM, Mortimer CH, Carr D (1974) Growth hormone release inhibiting hormone in acromegaly. Br Med J 1:352–355

    PubMed  Google Scholar 

  6. Bruining GJ, Bosschaart AN, Aarsen RSR, Lamberts SWJ, Sauer PJJ, Del Pozo E (1986) Normalization of glucose homeostasis by a long-acting somatostatin analog SMS 201–995 in a newborn with nesidioblastosis. Acta Endocrinol (Copenh) 113 [Suppl] 279:334–339

    Google Scholar 

  7. Cornblath M, Schwartz R (1976) Disorders of carbohydrate metabolism in infancy. WB Saunders, Philadelphia

    Google Scholar 

  8. Delemarre-Van De Waal HA, Veldkamp EJM, Schrander-Stumpel CTRM (1987) Long term treatment of an infant with nesidioblastosis using a somatostatin analogue. N Engl J Med 316:222–223

    PubMed  Google Scholar 

  9. Del Pozo E, Neufeld M, Schlüter K, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nüesch E, Marbach P, Cramer H, Kerp L (1986) Endocrine profile of a long-acting somatostatin derivate SMS 201–995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111:433–439

    PubMed  Google Scholar 

  10. Del Pozo E, Schluter K, Neufeld M, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nüesch E, Marbach P, Cramer H, Kerp L (1986) Endocrine profile and pharmacokinetics of the new Somatostatin analogue SMS 201–995. Acta Endocrinol 111: 433–439

    PubMed  Google Scholar 

  11. Heitz PU, Klöppel G, Häcki WH, Polak JM, Pearse AG (1977) Nesidioblastosis: the pathological basis of persistent hyperinsulinemic hypoglycemia in infants. Diabetes 26:632–642

    PubMed  Google Scholar 

  12. Hindmarsh PC, Brook CGD (1987) Short term management of an infant with nesidioblastosis using somatostatin analogue SMS 201–995. N Engl J Med 316:221–222

    PubMed  Google Scholar 

  13. Kirk JMW, Di Silvio L, Hindmarsh PC, Brook CGD (1988) Somatostatin analogue in short term management of hyperinsulinism. Arch Dis Child 63:1493–1494

    PubMed  Google Scholar 

  14. Moncrieff MW, Lacey KA, Malleson PN (1977) Management of prolonged hypoglycaemia in Beckwith's syndrome. Postgrad Med J 53:159

    PubMed  Google Scholar 

  15. Shiff D, Colle E, Wells D (1973) Metabolic aspects of the Beckwith-Wiedemann syndrome. J Pediatr 82:258–262

    PubMed  Google Scholar 

  16. Verschoor L, Uitterlinder P, Lamberts SWJ, Pozo E de (1986) On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clin Endocrinol 25:555–560

    Google Scholar 

  17. Willems PJ, Dijkstra I, Schierbeek HH, Berger R, Smit GPA (1988) Activation of fatty acid oxidation in the Silver-Russell syndrome and the Brachmann-de Lange Syndrome. Am J Med Genetics 30:865–873

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerver, W.J.M., Menheere, P.P.C.A., Schaap, C. et al. The effects of a somatostatin analogue on the metabolism of an infant with Beckwith-Wiedemann syndrome and hyperinsulinaemic hypoglycaemia. Eur J Pediatr 150, 634–637 (1991). https://doi.org/10.1007/BF02072623

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02072623

Key words

Navigation